MTOR and cancer: In MSK-IMPACT Clinical Sequencing Cohort, MTOR is mutated at a rate of 3% (329/10336) in metastatic cancer, which is also observed at the similar rate (2.9%, 292/10194) observed in China Pan-cancer Cohort (OrigiMed2020) (20, 22).